• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Travere Therapeutics (TVTX) Is Up 6.1% After FILSPARI Beats FSGS Launch Expectations

    Simply Wall St·08/20/2026 13:32:50
    Listen to the news
    • Travere Therapeutics recently reported that FILSPARI’s launch in FSGS is outperforming expectations with broad physician demand across a U.S. pool of more than 30,000 biopsy-confirmed patients.
    • The company is also pushing its rare disease pipeline forward with a Phase III trial of pegtibatinase in classical homocystinuria and adding civorebrutinib for multiple renal indications affecting roughly 130,000 patients, underscoring a widening kidney-focused franchise.
    • We’ll now examine how FILSPARI’s stronger-than-expected FSGS uptake could reshape Travere’s existing investment narrative built around its kidney portfolio.

    This technology could replace computers: discover 24 stocks that are working to make quantum computing a reality.

    Travere Therapeutics Investment Narrative Recap

    To own Travere today, you need to believe its kidney-focused portfolio, led by FILSPARI in IgA nephropathy and now FSGS, can eventually support a profitable, durable rare disease business despite current losses. The faster-than-expected FILSPARI FSGS launch reinforces the near-term growth story and supports the key catalyst of broader FILSPARI adoption, but it does not remove the central risk of heavy dependence on a single drug amid rising competition and ongoing R&D and SG&A spend.

    The most relevant recent announcement here is the FDA approval of FILSPARI for reducing proteinuria in FSGS, which converts a long-watched regulatory catalyst into a commercial one. Combined with the strong early FSGS uptake, this approval tightens the link between FILSPARI execution and Travere’s earnings trajectory, while the pegtibatinase Phase III readout and civorebrutinib renal program now sit as secondary, longer-dated levers behind the core kidney franchise.

    Yet beneath the strong FSGS launch, investors should be aware of the ongoing risk that FILSPARI concentration and rising kidney competition could...

    Read the full narrative on Travere Therapeutics (it's free!)

    Travere Therapeutics' narrative projects $1.4 billion revenue and $438.6 million earnings by 2029. This requires 34.3% yearly revenue growth and a $506.3 million earnings increase from -$67.7 million today.

    Uncover how Travere Therapeutics' forecasts yield a $68.36 fair value, a 4% upside to its current price.

    Exploring Other Perspectives

    TVTX 1-Year Stock Price Chart
    TVTX 1-Year Stock Price Chart

    Some of the most optimistic analysts were already assuming revenue could reach about US$1.7 billion by 2029, which is far more aggressive than consensus and leans heavily on FILSPARI’s rare kidney dominance; after this FSGS launch surprise, you may find your own view on that upside and on how exposed Travere remains to tighter pricing and competitive pressures landing somewhere in between.

    Explore 5 other fair value estimates on Travere Therapeutics - why the stock might be worth over 4x more than the current price!

    Reach Your Own Conclusion

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    • A great starting point for your Travere Therapeutics research is our analysis highlighting 3 key rewards that could impact your investment decision.
    • Our free Travere Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Travere Therapeutics' overall financial health at a glance.

    Want Some Alternatives?

    Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

    • The future of work is here. Discover the 38 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
    • Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 28 best rare earth metal stocks of the very few that mine this essential strategic resource.
    • We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.